The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

BofA Securities has recently reduced Hims & Hers Health Inc (HIMS) stock to Underperform rating, as announced on November 14, 2024, according to Finviz. Earlier, on August 22, 2024, Needham had ...

Shares of Hims & Hers Health jumped after the company added former Food and Drug Administration official Deb Autor to its board. The stock was up 8.8% at $21.02 in Monday trading. Shares have doubled ...

Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS), the leading health and wellness platform, today announced Deb Autor, ...

Deep-pocketed investors have adopted a bullish approach towards Hims & Hers Health HIMS, and it's something market players ...

The tech-heavy Nasdaq sustained a 2.2% drop, while the S&P 500 fell 1.3%. Both ended up slightly below their 21-day ...

We came across a bullish thesis on Hims & Hers Health, Inc. (HIMS) on Substack by The Dutch Investors. In this article, we ...